U.S. DIABETIC NEUROPATHY MARKET ANALYSIS

U.S. Diabetic Neuropathy Market, by Drug (Tricyclic Antidepressants (Amitriptyline, Nortyptyline, Imipramine, Desipramine), SSRI (Paroxetine, Citalopram), Anticonvulsants (Gabapentin, Pregabalin, Carbamazepine), Opioids (Tramadol, Tapentadol, Oksikodon), SNRIs (Duloxetine), Other Drugs (Capsaicin, Lidocaine, Botilinum Toxin)) by Type (Peripheral Neuropathy, Proximal Neuropathy, Autonomic Neuropathy, Focal Neuropathy), by Route of Administration (Oral, Topical, Injection (Intramuscular)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5356
Pages :160
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

U.S. Diabetic Neuropathy Market: Key Developments

Adoption of inorganic growth strategies such as drug approval from regulatory authorities such as the U.S. Food and Drug Administration is expected to drive the U.S. diabetic neuropathy market. For instance, in July 2019, Alembic Pharmaceuticals Limited, a pharmaceutical company, announced that they had received an approval from U.S. Food and Drugs Administration for or Pregabalin capsules, an oral and extended-release tablets, which indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older.